RenovoRx Inc reports results for the quarter ended in January - Earnings Summary

RenovoRx

13/05/2024 14:31

* RenovoRx Inc  RNXT.OQ  reported a quarterly adjusted loss
of 7
cents​​ per share for the quarter ended in January, higher than
the same quarter last year, when the company reported EPS of -36
cents.  The mean expectation of two analysts for the quarter was
for a loss of 14 cents per share. Wall Street expected
results to range from -16 cents to -13 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * RenovoRx Inc's reported EPS for the quarter was a loss
of 7
cents​.
    * The company reported a quarterly loss of $1.08 million.
    * RenovoRx Inc shares had risen by 8.2% this quarter and
lost 36.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for RenovoRx Inc is
$4.00 
This summary was machine generated from LSEG data May 13 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.14          -0.07          Beat
 Dec. 31 2023      -0.30          -0.31          Missed
 Sep. 30 2023      -0.30          -0.13          Beat
 Jun. 30 2023      -0.25          -0.31          Missed